Steven Sieber, MD
Anatomic Pathology & Clinical Pathology · Danbury, CTNPI 1942224043
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,044 and has fallen 97.0% since, to $31 in 2025. Among anatomic pathology & clinical pathology clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$186
- Merck$146
- AstraZeneca$107
- Sanofi-aventis U.S. LLC$74
- AMAG Pharmaceuticals, Inc.$72
- Ipsen Biopharmaceuticals, Inc$72
- plus $779 from 22 others
What the payments were for
- Food & beverage$1,36395%
- Education$725%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 9 | $186 |
| Merck | 5 | $146 |
| AstraZeneca(2 entities) | 7 | $107 |
| Sanofi-aventis U.S. LLC | 3 | $74 |
| AMAG Pharmaceuticals, Inc. | 4 | $72 |
| Ipsen Biopharmaceuticals, Inc | 4 | $72 |
| Bayer | 4 | $70 |
| Puma Biotechnology, Inc. | 3 | $57 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $56 |
| Exelixis Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Clovis Oncology, Inc. | 3 | $49 |
| Amgen | 3 | $44 |
| Tesaro, Inc. | 2 | $44 |
| Novocure Inc. | 3 | $41 |
| Eisai Inc. | 2 | $36 |
| Seagen Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Array Biopharma Inc | 1 | $33 |
| Caris MPI, Inc. | 1 | $31 |
| Bristol Myers Squibb | 2 | $27 |
| Taiho Oncology, Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 2 | $24 |
| AbbVie | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Incyte Corporation | 1 | $12 |
| EMD Serono, Inc. | 1 | $11 |
How this compares
$1,435 in reported general payments places this provider in the 90th percentile of 94 anatomic pathology & clinical pathology providers in Connecticut.
See all anatomic pathology & clinical pathology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other anatomic pathology & clinical pathology in Danbury
- Jessica DodgeDanbury$231
- Gunjan GuptaDanbury$206
- Jeffrey WestDanbury$169
- Hani El FanekDanbury$60
- Kurt SchalperNew Haven$138K
- Marie RobertNew Haven$128K
- Robert BabkowskiStamford$76K
- Mina XuNew Haven$9K
- Chen LiuNew Haven$9K
- Gilbert MoeckelNew Haven$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.